Stock Events

Stock Events

Aligos Therapeutics 

€6.82
0
-€0.42-5.8% Wednesday 06:02

Statistics

Day High
6.82
Day Low
6.82
52W High
11.2
52W Low
3.96
Volume
0
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q4 2025
Next
-2.14
-1.98
-1.81
-1.65
Expected EPS
-1.8744115877999998
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5WK0.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap9.12B
Arrowhead Pharmaceuticals focuses on developing RNAi therapeutics for diseases with a similar focus to Aligos, making them direct competitors in the RNAi and NASH space.
Moderna
MRNA
Mkt Cap20.21B
Moderna is involved in mRNA therapeutics, a space that overlaps with Aligos's work on liver diseases, including hepatitis B, positioning them as competitors in the biotech sector.
Vir Biotechnology
VIR
Mkt Cap1.52B
Vir Biotechnology specializes in infectious diseases, including hepatitis B, which is a direct area of focus for Aligos, making them competitors in the infectious disease market.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences has a strong portfolio in liver diseases, including hepatitis B and NASH, directly competing with Aligos's therapeutic areas.
Arbutus Biopharma
ABUS
Mkt Cap811.23M
Arbutus Biopharma is focused on developing cures for hepatitis B, directly competing with Aligos in the HBV therapeutic area.
BioNTech
BNTX
Mkt Cap24.15B
BioNTech SE, though known for their COVID-19 vaccine, also works on infectious disease therapeutics, overlapping with Aligos's focus areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.97B
Vertex Pharmaceuticals has expanded into liver diseases, including NASH, positioning them as competitors to Aligos in the liver disease space.
Novartis
NVS
Mkt Cap297.35B
Novartis AG has a broad portfolio that includes treatments for liver diseases, making them a competitor in the broader pharmaceutical market against Aligos.
Pfizer
PFE
Mkt Cap153.13B
Pfizer has a diverse drug portfolio that includes treatments for infectious diseases, potentially competing with Aligos in areas like hepatitis B.

About

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Show more...
CEO
Dr. Lawrence M. Blatt MBA, Ph.D.
Employees
82
Country
United States
ISIN
US01626L2043

Listings

STU
DE
5WK0.STU
MU
DE
5WK0.MU
F
DE
5WK0.F
XNAS
US
ALGS

0 Comments

Share your thoughts

FAQ

What is Aligos Therapeutics stock price today?▼
The current price of 5WK0.MU is €6.82 EUR — it has decreased by -5.8% in the past 24 hours. Watch Aligos Therapeutics stock price performance more closely on the chart.
What is Aligos Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Aligos Therapeutics stocks are traded under the ticker 5WK0.MU.
Is Aligos Therapeutics stock price growing?▼
5WK0.MU stock has fallen by -1.16% compared to the previous week, the month change is a +3.33% rise, over the last year Aligos Therapeutics has showed a +67.98% increase.
When is the next Aligos Therapeutics earnings date?▼
Aligos Therapeutics is going to release the next earnings report on May 12, 2026.
What were Aligos Therapeutics earnings last quarter?▼
5WK0.MU earnings for the last quarter are -1.65 EUR per share, whereas the estimation was -2.14 EUR resulting in a +23.19% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Aligos Therapeutics have?▼
As of April 16, 2026, the company has 82 employees.
In which sector is Aligos Therapeutics located?▼
Aligos Therapeutics operates in the Other sector.
When did Aligos Therapeutics complete a stock split?▼
Aligos Therapeutics has not had any recent stock splits.
Where is Aligos Therapeutics headquartered?▼
Aligos Therapeutics is headquartered in South San Francisco, United States.